Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 271 results for obesity

  1. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

  2. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

  3. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  4. Butterfly iQ+ for diagnostic ultrasound imaging (MIB254)

    NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .

  5. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

  6. Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)

    This quality standard has been updated and replaced by NICE quality standard 212.

  7. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  8. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.

  9. Renal and ureteric stones: assessment and management (NG118)

    This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.

  10. Care and support of people growing older with learning disabilities (NG96)

    This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

  11. Workplace health: management practices (NG13)

    This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.

  12. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  13. Video laryngoscopes to help intubation in people with difficult airways (MIB167)

    NICE has developed a medtech innovation briefing (MIB) on video laryngoscopy to help intubation in people with difficult airways .

  14. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

  15. OrganOx metra for liver transplant (MIB275)

    NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .